Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis

• Main Authors: Xiaoyu Qian (Author), Xiaodan Guo (Author), Ting Li (Author), Wei Hu (Author), Lin Zhang (Author), Caisheng Wu (Author), Feng Ye (Author)
• Formato: Livro
• Publicado em: Frontiers Media S.A., 2022-08-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Background: Epidermal growth factor receptor (EGFR) mutations are common in patients with non-small-cell lung cancer (NSCLC), particularly in Asian populations. Tyrosine kinase inhibitors (TKIs) are a first-line treatment in patients with mutant EGFR, but their use is often accompanied by drug resis...